Expert Opinion on Investigational Drugs
Impact Factor Trend (2018–2026)
Clarivate IF trend for Expert Opinion on Investigational Drugs
SCImago Journal Rank citation prestige weighting
126 papers with at least that number of citations each
Aims & Scope
Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
Special Issues
Calls for PapersNo active Calls for Papers found for this journal.
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
PHARMACOLOGY & PHARMACY
PHARMACOLOGY & PHARMACY
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Journal Metrics & Citation Visualizations
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Academic Intelligence Overview & Context
ImpaQ AnalysisExpert Opinion on Investigational Drugs (acronym: eoid, abbr: EXPERT OPIN. INVEST. DRUGS, ISSN: 1354-3784) is a peer-reviewed international scholarly journal in the field of Medicine, published by Taylor and Francis Ltd. in England since 1994. The periodical holds a Journal Impact Factor (JIF) of 4.30, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 1.199 (Q1), an H-index of 126.
The journal enforces rigorous peer evaluation with a publication frequency of Monthly, an annual output of approximately 97 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,479 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics